Global and United States Prostate Cancer PARP Inhibitor Drugs Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Prostate Cancer PARP Inhibitor Drugs Market Report & Forecast 2024-2034
Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanismsdirect inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.
Market Analysis and InsightsGlobal and United States Prostate Cancer PARP Inhibitor Drugs Market
This report focuses on global and United States Prostate Cancer PARP Inhibitor Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Prostate Cancer PARP Inhibitor Drugs revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the Prostate Cancer PARP Inhibitor Drugs revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Prostate Cancer PARP Inhibitor Drugs include AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc. The global five biggest players hold a share of % in 2024.
Global Prostate Cancer PARP Inhibitor Drugs Scope and Market Size
Prostate Cancer PARP Inhibitor Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Prostate Cancer PARP Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Prostate Cancer PARP Inhibitor Drugs market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other
Hospital
Specialty Clinic
other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Prostate Cancer PARP Inhibitor Drugs definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Prostate Cancer PARP Inhibitor Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Prostate Cancer PARP Inhibitor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer PARP Inhibitor Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States Prostate Cancer PARP Inhibitor Drugs Market
This report focuses on global and United States Prostate Cancer PARP Inhibitor Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Prostate Cancer PARP Inhibitor Drugs revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the Prostate Cancer PARP Inhibitor Drugs revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Prostate Cancer PARP Inhibitor Drugs include AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc and Jiangsu Hengrui Pharmaceuticals Co., Ltd, etc. The global five biggest players hold a share of % in 2024.
Global Prostate Cancer PARP Inhibitor Drugs Scope and Market Size
Prostate Cancer PARP Inhibitor Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Prostate Cancer PARP Inhibitor Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Prostate Cancer PARP Inhibitor Drugs market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
AstraZeneca
Merck & Co., Inc
GSK
Pfizer
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene, Inc
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Segment by Type
Lynparza
Zejula
Talzenna
Fluzoparib
PamiPali
Other
Segment by Application
Hospital
Specialty Clinic
other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Prostate Cancer PARP Inhibitor Drugs definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Prostate Cancer PARP Inhibitor Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Prostate Cancer PARP Inhibitor Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer PARP Inhibitor Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices